Chronic Migraine Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad
DelveInsight’s “Chronic Migraine Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Migraine, historical and forecasted epidemiology as well as the Chronic Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Chronic Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Migraine Market Forecast
Some of the key facts of the Chronic Migraine Market Report:
- The Chronic Migraine market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- All participants who had a headache within the previous 12 months prior to the survey between October 2019 and March 2020 were included in the BURDEN 2020 study, which was developed by the RKI and conducted by the market and social research institute USUMA GmbH. According to the survey, 40.4% of men and 57.5% of women reported having headaches in the previous 12 months. In both men and women, 6.0% and 1.2%, respectively, suffered from migraines
- Migraine is the most prevalent neurological condition, according to German research community funding headache research in Essen 2021. Around 14% of German women and 8% of German men are affected. About 2% of people have a chronic form of the condition
- Key Chronic Migraine Companies: Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
- Key Chronic Migraine Therapies: AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
- The Chronic Migraine epidemiology based on gender analyzed that the prevalence of migraine in female is slightly higher than male
- The Chronic Migraine market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Migraine pipeline products will significantly revolutionize the Chronic Migraine market dynamics.
Chronic Migraine Overview
Migraine, a main headache illness, is a neurological condition that commonly manifests as severe, incapacitating headaches among other symptoms. It affects all ages and frequently runs in families. There are primarily two types: acute migraine and chronic migraine.
Get a Free sample for the Chronic Migraine Market Report
https://www.delveinsight.com/sample-request/migraine-market
Chronic Migraine Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Migraine Epidemiology Segmentation:
The Chronic Migraine market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Chronic Migraine
- Prevalent Cases of Chronic Migraine by severity
- Gender-specific Prevalence of Chronic Migraine
- Diagnosed Cases of Episodic and Chronic Chronic Migraine
Download the report to understand which factors are driving Chronic Migraine epidemiology trends @ Chronic Migraine Epidemiology Forecast
Chronic Migraine Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Migraine market or expected to get launched during the study period. The analysis covers Chronic Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Migraine Therapies and Key Companies
- AIMOVIG: Amgen
- Fremanezumab: Teva Pharmaceuticals
- Galcanezumab: Eli Lilly and Company
- propranolol LA: Anne Lindblad
- Atogepant: Allergan
- LBR-101: Teva Branded Pharmaceutical
- Atogepant: AbbVie
- Galcanezumab: Eli Lilly and Company
- Marcaine: Tian Medical Inc.
- Atogepant: Allergan
- Galcanezumab: Eli Lilly and Company
- Eptinezumab: H. Lundbeck A/S
- TNX-1900: Tonix Pharmaceuticals, Inc.
- IONIS-PKKRx (ISIS 546254): Ionis Pharmaceuticals, Inc.
Discover more about therapies set to grab major Chronic Migraine market share @ Chronic Migraine Treatment Market
Scope of the Chronic Migraine Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Chronic Migraine Companies: Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
- Key Chronic Migraine Therapies: AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
- Chronic Migraine Therapeutic Assessment: Chronic Migraine current marketed and Chronic Migraine emerging therapies
- Chronic Migraine Market Dynamics: Chronic Migraine market drivers and Chronic Migraine market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Chronic Migraine Unmet Needs, KOL’s views, Analyst’s views, Chronic Migraine Market Access and Reimbursement
To know more about Chronic Migraine companies working in the treatment market, visit @ Chronic Migraine Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Migraine Market Report Introduction
2. Executive Summary for Chronic Migraine
3. SWOT analysis of Chronic Migraine
4. Chronic Migraine Patient Share (%) Overview at a Glance
5. Chronic Migraine Market Overview at a Glance
6. Chronic Migraine Disease Background and Overview
7. Chronic Migraine Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Migraine
9. Chronic Migraine Current Treatment and Medical Practices
10. Chronic Migraine Unmet Needs
11. Chronic Migraine Emerging Therapies
12. Chronic Migraine Market Outlook
13. Country-Wise Chronic Migraine Market Analysis (2019–2032)
14. Chronic Migraine Market Access and Reimbursement of Therapies
15. Chronic Migraine Market Drivers
16. Chronic Migraine Market Barriers
17. Chronic Migraine Appendix
18. Chronic Migraine Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services